Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMUC4064A in Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
NCT02146313Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2014
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DMUC4064A in ovarian cancer and pancreatic cancer (PC) (3 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities, Maximum Tolerated Dose of DMUC4064A and 2 more. Started Jun 2014; status: completed.
02
Drugs
DMUC4064A
03
Conditions
ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02146313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146313.